Cybin (HELP) Cash from Financing Activities (2020 - 2026)
Cybin (HELP) posted quarterly Cash from Financing Activities of -$169000.0 for Q1 2026, down 101.16% year-on-year from $14.6 million in Q1 2025, and down 100.12% on a QoQ basis from $143.7 million in Q4 2025.
Cybin (HELP) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Cybin (HELP) has reported Cash from Financing Activities for 7 consecutive years, with -$169000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.16% year-over-year to -$169000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.2 million (up 1310.85% YoY) and the FY2026 annual result came in at $198.2 million, up 1306.45% from the prior year.
- Cash from Financing Activities eased to -$169000.0 in Q1 2026 per HELP's latest filing, from $143.7 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for HELP reached as high as $143.7 million in Q4 2025 and fell as low as -$271000.0 in Q3 2024.
- A 5-year average of $27.1 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities sank 106.56% — and 2025, when it soared 112403.12%.
- Year by year, Cash from Financing Activities stood at $2.5 million in 2022, then soared by 1045.56% to $29.2 million in 2023, then plunged by 100.44% to -$128000.0 in 2024, then surged by 112403.12% to $143.7 million in 2025, then tumbled by 100.12% to -$169000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$169000.0, $143.7 million, and $27000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | -169,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169,000.00 |
| Mar 31, 2026 | -169,000.00 |
| Dec 31, 2025 | 143.75 Mn |
| Dec 31, 2025 | 143.75 Mn |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 54.63 Mn |
| Jun 30, 2025 | 54.63 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Dec 31, 2024 | -128,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Sep 30, 2024 | -271,000.00 |
| Sep 30, 2024 | -271,000.00 |
| Jun 30, 2024 | -172,000.00 |
| Jun 30, 2024 | -172,000.00 |
| Mar 31, 2024 | 141.64 Mn |
| Mar 31, 2024 | 141.64 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Dec 31, 2023 | 29.19 Mn |